Lisata Therapeutics Q3 2024 net loss $4.9M; cash runway into early 2026; multiple trial updates

LISATA THERAPEUTICS, INC.

2024-Q3 EPS reported -$1.85

Net loss of $4.9M in Q3 2024, improved from $5.3M loss in Q3 2023.
Cash, cash equivalents and marketable securities of $35.9M as of Sep 30, 2024; funds operations into early 2026.
Phase 2b ASCEND trial (mPDAC) Cohort A interim data expected at ASCO GI in Jan 2025; Cohort B data mid-2025.
BOLSTER Phase 2a first-line cholangiocarcinoma enrollment complete ahead of plan; topline data mid-2025; second-line cohort added.
Entered research collaborations for certepetide: endometriosis (Univ. of Cincinnati) and melanoma (Valo Therapeutics).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.